Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) crossed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $2.33 and traded as high as $2.43. Vistagen Therapeutics shares last traded at $2.41, with a volume of 65,916 shares changing hands.
Vistagen Therapeutics Price Performance
The stock has a market capitalization of $73.60 million, a price-to-earnings ratio of -1.72 and a beta of 0.67. The business's fifty day moving average price is $2.32 and its 200-day moving average price is $2.61.
Institutional Trading of Vistagen Therapeutics
Several hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its holdings in Vistagen Therapeutics by 4,826,425.0% during the 4th quarter. JPMorgan Chase & Co. now owns 772,244 shares of the company's stock worth $2,278,000 after acquiring an additional 772,228 shares during the period. Nantahala Capital Management LLC boosted its stake in shares of Vistagen Therapeutics by 30.6% in the 4th quarter. Nantahala Capital Management LLC now owns 1,981,980 shares of the company's stock valued at $5,847,000 after purchasing an additional 464,284 shares in the last quarter. Almitas Capital LLC purchased a new stake in shares of Vistagen Therapeutics in the 4th quarter valued at $751,000. Blair William & Co. IL boosted its stake in shares of Vistagen Therapeutics by 11.3% in the 4th quarter. Blair William & Co. IL now owns 98,466 shares of the company's stock valued at $290,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new stake in Vistagen Therapeutics during the 4th quarter valued at $123,000. Institutional investors own 78.39% of the company's stock.
Vistagen Therapeutics Company Profile
(
Get Free Report)
Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.
Read More
Before you consider Vistagen Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vistagen Therapeutics wasn't on the list.
While Vistagen Therapeutics currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
